The potential role of PKC β in diabetic retinopathy and macular edema

Survey of Ophthalmology

Volumn 47, Issue SUPPL. 2, 2002, Pages

  Aiello, Lloyd Paul ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

Diabetes; Diabetic retinopathy; Macular edema; Protein kinase C

Indexed keywords

GROWTH FACTOR; ISOENZYME; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN;

AGE; ARTICLE; BIOCHEMISTRY; BLINDNESS; CELLULAR PARAMETERS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; ISCHEMIA; LASER COAGULATION; MEDICAL RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA ISCHEMIA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; TREATMENT INDICATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANIMALS; DIABETIC RETINOPATHY; ENZYME INHIBITORS; HUMANS; INDOLES; ISOENZYMES; MACULAR EDEMA, CYSTOID; MALEIMIDES; PROTEIN KINASE C;

EID: 0036939182     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00391-0     Document Type: Article

References (48)

1. Adamis A.P., Shima D.T., Tolentino M.J.et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 114:1996;66-71.
2. Aiello L.P., Bursell S., Devries T. Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes. 48:1999;A19.
3. Aiello L.P., Bursell S.E., Clermont A.et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 46:1997;1473-1480.
4. Aiello L.P., Gardner T.W., King G.L.et al. Diabetic retinopathy. Diabetes Care. 21:1998;143-156.
5. Aiello L.P., Pierce E.A., Foley E.D.et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 92:1995;10457-10461.
6. American Diabetes Association Diabetic retinopathy. Diabetes Care. 23(Suppl 1):1993;S73-S76.
7. Barouch F.C., Miyamoto K., Allport J.R.et al. Integrin mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthamol Vis Sci. 4:2000;1153-1158.
8. Bursell S.-E., King G.L. Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diab Res Clin Pract. 45:1999;169-182.
9. Bursell S.E., Clermont A.C., Kinsley B.T.et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 37:1996;886-897.
10. Cameron N.E., Cotter M.A. Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats. interaction with oxidative stress and essential fatty acid dysmetabolism Diabetes Metab Res Rev. 18:2002;315-323.
11. Cogan D.G., Toussaint D., Kubawara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol. 66:1961;100-112.
12. Danis R.P., Bingaman D.P., Jirousek M., Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci. 39:1998;171-179.
13. Demolle D., de Suray J.M., Onkelinx C. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC beta inhibitor, in healthy subjects. Clin Pharmacol Ther. 65:1999;189.
14. Demolle D., de Suray J.M., Vandenhende F., Onkelinx C. LY333531 single escalating oral dose study in health volunteers. Diabetologia. 41(Suppl 1):1998;A354.
15. Denis U., Lecomte M., Paget C.et al. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture. involvement of diacylglycerol/ceramide production and oxidative stress induction Free Radic Biol Med. 33:2002;236-247.
16. Ferris F.L., Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 28(Suppl):1984;452-461.
17. Ferris F.L. 3rd How effective are treatments for diabetic retinopathy? JAMA. 269:1993;1290-1291.
18. Ferris F.L. 3rd, Davis M.D., Aiello L.M. Treatment of diabetic retinopathy. N Engl J Med. 341:1999;667-678.
19. Friedman E.A. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care. 22(Suppl 2):1999;B65-B71.
20. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 19:1996;257-267.
21. Inoguchi T., Battan R., Handler E.et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats. differential reversibility to glycemic control by islet cell transplantation Proc Natl Acad Sci USA. 89:1992;11059-11063.
22. Ishii H., Jirousek M.R., Koya D.et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 272:1996;728-731.
23. Ishii H., Koya D., King G.L. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med. 76:1998;21-31.
24. Jirousek M.R., Gillig J.R., Gonzalez C.M.et al. S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno- 1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues. isozyme selective inhibitors of protein kinase C beta J Med Chem. 39:1996;2664-2671.
25. Kamei J., Mizoguchi H., Narita M., Tseng L.F. Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opin Investig Drugs. 10:2001;1653-1664.
26. Klein R., Klein B.E., Moss S.E.et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 260:1988;2864-2871.
27. Kowluru R.A. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol. 38:2001;179-185.
28. Koya D., Haneda M., Nakagawa H.et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14:2000;439-447.
29. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes. 47:1998;859-866.
30. Leitges M., Schmedt C., Guinamard R.et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science. 273:1996;788-791.
31. Miller J.W., Adamis A.P., Aiello L.P. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 13:1997;37-50.
32. Morgan C.M., Schatz H. Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation. Ophthalmology. 96:1989;96-103.
33. Naruse K., King G.L. Protein kinase C and myocardial biology and function. Circ Res. 86:2000;1104-1106.
34. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
35. Ozaki H., Seo M.S., Ozaki K.et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 156:2000;697-707.
36. Patz A., Schatz H., Berkow J.W.et al. Macular edema - an overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol. 77:1973;OP34-OP42.
37. Robinson G.S., Pierce E.A., Rook S.L.et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 93:1996;4851-4856.
38. Rutledge B.K., Wallow I.H., Poulsen G.L. Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema. Arch Ophthalmol. 111:1993;608-613.
39. Seo M.S., Kwak N., Ozaki H.et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol. 154:1999;1743-1753.
40. Shah S.S., Schachat A.P., Murphy R.P., Fine S.L. The evolution of argon laser photocoagulation scars in patients with the ocular histoplasmosis syndrome. Arch Ophthalmol. 106:1988;1533-1536.
41. Shiba T., Inoguchi T., Sportsman J.R.et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 265:1993;E783-E793.
42. Spranger J., Osterhoff M., Reimann M.et al. Loss of the antiangiogenic pigment epithelial derived factor in patients with angiogenic eye disease. Diabetes. 50:2001;2641-2645.
43. Suzuma K., Takahara N., Suzuma I.et al. Characterization of protein kinase C beta isoforms action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA. 99:2002;721-726.
44. Wakasaki H., Koya D., Schoen F.J.et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA. 94:1997;9320-9325.
45. Way K.J., Chou E., King G.L. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci. 21:2000;181-187.
46. Way K.J., Katai N., King G.L. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 18:2001;945-959.
47. Ways D.K., Sheetz M.J. The role of protein kinase C in the development of the complications of diabetes. Vitam Horm. 60:2000;149-193.
48. Xia P., Aiello L.P., Ishii H.et al. Characterization of vascular endothelial growth factors effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 98:1996;2018-2026.